Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.
Clinical Trials Arena on MSN
IntraBio’s ataxia-telangiectasia drug meets endpoints in pivotal trial
If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.
A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The trial will evaluate VO659, an antisense ...
Worldwide, only a handful of patients are known to suffer from episodic ataxia type 6, a neurological disease that causes transient loss of muscle control. The cause lies in a mutation that changes a ...
The Department of Neurology at Niigata University and the National Center of Neurology and Psychiatry (NCNP) have identified pathogenic thresholds for the CAG repeat units (RU) of the CACNA1A gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results